Navigation Links
Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
Date:8/27/2009

TOSU, SAGA, Japan, Aug. 27 /PRNewswire/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530) today announced the expiration of the subsequent offering period and completion of the tender offer for all outstanding shares of Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) common stock at a price per share of $16.50. The subsequent offering period expired at 12:00 midnight, New York City time, on Wednesday, August 26, 2009 and was not extended.

As of such time, an aggregate of 22,320,889 shares of Noven's common stock, representing approximately 89.18% of Noven's outstanding shares, had been tendered pursuant to the offer. All shares tendered have been accepted for payment and payment for such shares has been or will be made promptly in accordance with the terms of the tender offer.

Hisamitsu also announced that it intends to exercise the option granted by Noven under the merger agreement to purchase from Noven, at a price per share of $16.50, the number of newly issued shares of Noven's common stock that, when added to the number of shares owned by Northstar Merger Sub at the time the option is exercised, will constitute one share more than 90% of Noven's then outstanding shares.

Hisamitsu intends to complete the acquisition of Noven through a short-form merger of Northstar Merger Sub with and into Noven pursuant to the Delaware General Corporation Law, which will not require a vote or meeting of Noven's stockholders, as soon as practicable after the exercise of such option, at which time Noven will become a wholly-owned subsidiary of Hisamitsu U.S., Inc. Following the merger, Noven's common stock will cease to be traded on the NASDAQ Global Stock Market.

About Hisamitsu

Hisamitsu Pharmaceutical Co., Inc. is a leading pharmaceutical company that develops and markets prescription and over-the-counter ("OTC") pharmaceutical products using transdermal delivery systems technology. Its leading product in prescription pharmaceuticals is its Mohrus(R) series (ketoprofen patch for pain), and its leading brand in the OTC business is Salonpas(R). The company was founded in 1847 and is located in Saga, Japan. Additional information is available through its corporate website, http://www.hisamitsu.co.jp.


'/>"/>
SOURCE Hisamitsu Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
2. Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
3. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
4. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Baird Healthcare Investor Conferences on September 9 and September 10, 2009
6. Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
7. Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
8. Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals
9. Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
10. Raptor Pharmaceuticals Raises $5 Million
11. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: